Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

81. Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines

Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions One relevant non-randomized study regarding the use of maxillary artery ligation for the treatment of cluster headaches was identified. No relevant health technology assessment reports

Health Technology Assessment (HTA) Database.2014

82. OnabotulinumtoxinA (Botox - Allergan Inc.) indication: chronic migraine

OnabotulinumtoxinA (Botox - Allergan Inc.) indication: chronic migraine OnabotulinumtoxinA (Botox - Allergan Inc.) indication: chronic migraine OnabotulinumtoxinA (Botox - Allergan Inc.) indication: chronic migraine CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. OnabotulinumtoxinA (Botox - Allergan Inc.) indication: chronic (...) migraine. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that onabotulinumtoxinA (OA) not be listed for the management of chronic migraine. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Botulinum Toxins, Type A; Chronic Disease; Migraine Disorderss Language Published English Country of organisation Canada Province or state Ontario English summary

Health Technology Assessment (HTA) Database.2014

83. Controversies in Migraine Management

Controversies in Migraine Management Controversies in Migraine Management A Technology Assessment Final Report August 19, 2014 Completed by: Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2014 AUTHORS: Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine Department of Medicine University of California San Francisco Daniel A. Ollendorf, PhD Chief Review Officer, Institute for Clinical and Economic Review Jed Weissberg (...) Introduction 1 1. Background 2 2. Clinical Guidelines 9 3. Coverage Policies 11 4. Previous Systematic Reviews and Technology Assessments 16 5. Ongoing Studies 18 6. Evidence Review (Methods & Results) 22 7. Model of Clinical and Economic Outcomes of Treatment Strategies for Migraine 35 8. CTAF Voting Questions and Discussion 53 References 62 APPENDIX 73 ©Institute for Clinical and Economic Review, 2014 iv Abbreviations used in this report AEs: Adverse events AHRQ: Agency for Healthcare Research

California Technology Assessment Forum2014

84. Treating migraine attacks: new evidence to guide choices

Treating migraine attacks: new evidence to guide choices Treating migraine attacks: new evidence to guide choices - Evidently Cochrane Search and hit Go By June 6, 2014 // Hildegard von Bingen Image found at www.catholicworldreport.com Trust a doctor to put a dampener on things. Just imagine, there you are having visions where “Heaven was opened and a fiery light of exceeding brilliance came and permeated my whole brain, and inflamed my whole heart and my whole breast, not like a burning (...) but like a warming flame, as the sun warms anything its rays touch.” This was the lot of a 12th century abbess, Hildegard von Bingen. According to neurologist Oliver Sacks, the poor dear was just experiencing migraines. Whether Hildegard was a migraine sufferer remains speculative and this could be a case of historical over diagnosis. I’m not convinced she would have wanted to put a stop to these experiences, but if you are prone to migraines I’m sure you’ll want to know what might work for you

Evidently Cochrane2014

85. OnabotulinumtoxinA - Migraine, chronic

OnabotulinumtoxinA - Migraine, chronic Common Drug Review CDEC Meeting — March 19, 2014; CDEC Reconsideration — May 21, 2014 Page 1 of 6 Notice of Final Recommendation — May 28, 2014 © 2014 CADTH CDEC FINAL RECOMMENDATION ONABOTULINUMTOXINA (Botox — Allergan Inc.) Indication: Chronic Migraine Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that onabotulinumtoxinA (OA) not be listed for the management of chronic migraine. Reason for the Recommendation: 1. Two randomized (...) controlled trials (RCTs) (PREEMPT-1 and PREEMPT-2) demonstrated that OA was statistically superior to placebo for improving health-related quality of life and reducing the number of headache days and migraine/probable migraine days in patients with chronic migraine; however, the absolute difference between the OA and placebo groups was relatively small for this chronic condition (range of ?1.4 to ?2.3 headache days per 28-day period and ?1.6 to ?2.3 migraine/probable migraine per 28-day period). 2

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2014

86. What clinical clues differentiate migraine from sinus headaches?

What clinical clues differentiate migraine from sinus headaches? What clinical clues differentiate migraine from sinus headaches? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What clinical clues differentiate migraine from sinus headaches? View/ Open Date 2013-12 Format Metadata Abstract Evidence-based answer (...) : Patients with sinus headaches have thick nasal discharge, fever, chills, sweats, or abnormally malodorous breath (SOR: B, cross-sectional study). The 5 symptoms that are most predictive of migraine are: pulsatile quality, duration of 4 to 72 hours, unilateral location, nausea or vomiting, and disabling intensity (SOR: B, retrospective cohort). As the number of these symptoms increases, so too, does the likelihood that the patient has a migraine (SOR: B, systematic review of retrospective cohort studies

Clinical Inquiries2014

87. Transcranial magnetic stimulation for treating and preventing migraine (IPG477)

Transcranial magnetic stimulation for treating and preventing migraine (IPG477) Transcranial magnetic stimulation for treating and preventing migraine | Guidance and guidelines | NICE Transcranial magnetic stimulation for treating and preventing migraine Interventional procedures guidance [IPG477] Published date: January 2014 Share Guidance (International Headache Society 2004) provides a classification of migraine types. Current treatment for migraine aims to prevent or stop episodes

National Institute for Health and Clinical Excellence - Interventional Procedures2014

88. Migraine prophylaxis: flunarizine

Migraine prophylaxis: flunarizine Migr Migraine proph aine prophylaxis: flunarizine ylaxis: flunarizine Evidence summary Published: 30 September 2014 nice.org.uk/guidance/esuom33 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Flunarizine (...) is a calcium channel blocker that reduces smooth muscle spasm. Overall, the studies included in this evidence summary suggest that flunarizine is as effective as propranolol or topiramate at reducing the frequency of migraines in adults. In children, flunarizine was more effective than placebo at reducing migraine frequency, and as effective as nimodipine, aspirin, propranolol or dihydroergotamine. However, all of the studies in children were small and of poor quality. The most common adverse effect of flunarizine

National Institute for Health and Clinical Excellence - Advice2014

89. Botulinum toxin type A for prophylactic treatment of chronic migraine

Botulinum toxin type A for prophylactic treatment of chronic migraine Botulinum toxin type A for prophylactic treatment of chronic migraine Botulinum toxin type A for prophylactic treatment of chronic migraine Kim M, Danielsson A, Ekelund A-C, Kemppainen E, Sjögren P, Svanberg T, Szalo G, Samuelsson O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kim M (...) , Danielsson A, Ekelund A-C, Kemppainen E, Sjögren P, Svanberg T, Szalo G, Samuelsson O. Botulinum toxin type A for prophylactic treatment of chronic migraine. Gothenburg: The Regional Health Technology Assessment Centre (HTA-centrum). HTA-rapport 2014:70. 2014 Authors' conclusions It is uncertain whether BTX reduces the frequency of headache days, reduces acute headache pain medication, or has any impact on functioning in comparison with saline. Botulin toxin A injection may result in little

Health Technology Assessment (HTA) Database.2014

90. Migraine

Migraine TREATMENT OF MIGRAINE IN PREGNANCY 0344 892 0909 TREATMENT OF MIGRAINE IN PREGNANCY (Date of issue: August 2016 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Migraine is common in women of reproductive age and may occur (...) in pregnancy. It has been estimated that in up to 80% of women who suffer migraines, both the frequency and severity of attacks improve during the second and third trimesters of pregnancy, thus routine prophylaxis with therapies such as topiramate or propranolol is not recommended during pregnancy. However, in some cases migraine may fail to improve or worsen. In some women migraine presents for the first time during pregnancy. Migraine itself does not appear to increase the risk of spontaneous

UK Teratology Information Service2014

91. Homeopathic remedies in the treatment of migraine and osteoarthritis

Homeopathic remedies in the treatment of migraine and osteoarthritis File Name: AS Homeopathy Version: 1.0 Date: 19 August 2014 Produced by: Secretariat Page: 1 Review date: n/a Advice Statement 003/14 August 2014 Are homeopathic remedies clinically and cost effective in the treatment of migraine and osteoarthritis? This advice has been produced following completion of evidence note 53 by Healthcare Improvement Scotland, in response to an enquiry from the NHS Highland Clinical Advisory Group (...) clinics or the Centre for Integrative Care (CIC) (formerly Glasgow Homeopathic Hospital). Not all NHSScotland health boards provide funding for homeopathy; investment varies widely among those that do, and individual boards have begun to review funding for homeopathy services. Clinical effectiveness ? Evidence of clinical effectiveness was reviewed from systematic reviews of four placebo controlled randomised trials of homeopathy for migraine published between 1991 and 1997; and systematic reviews

SHTG Advice Statements2014

92. Systematic review and meta-analysis: Migraine is a marker for risk of both ischaemic and haemorrhagic stroke

Systematic review and meta-analysis: Migraine is a marker for risk of both ischaemic and haemorrhagic stroke Migraine is a marker for risk of both ischaemic and haemorrhagic stroke | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Migraine is a marker for risk of both ischaemic and haemorrhagic stroke Article Text Aetiology Systematic review and meta-analysis Migraine is a marker for risk of both ischaemic and haemorrhagic stroke Tobias Kurth Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Sacco S , Ornello

Evidence-Based Medicine (Requires free registration)2014

93. OnabotulinumtoxinA (Botox ? Allergan Inc.) indication: chronic migraine

OnabotulinumtoxinA (Botox ? Allergan Inc.) indication: chronic migraine OnabotulinumtoxinA (Botox — Allergan Inc.) indication: chronic migraine OnabotulinumtoxinA (Botox — Allergan Inc.) indication: chronic migraine CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. OnabotulinumtoxinA (Botox — Allergan Inc.) indication: chronic (...) migraine. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0345. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that onabotulinumtoxinA (OA) not be listed for the management of chronic migraine. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Botulinum Toxins, Type As; Migraine Disorders Language Published English Country of organisation Canada Province or state Ontario English summary

Health Technology Assessment (HTA) Database.2014

94. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial.

Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. IMPORTANCE: Early, safe, effective, and durable evidence-based interventions for children and adolescents with chronic migraine do not exist. OBJECTIVE: To determine the benefits of cognitive behavioral therapy (CBT) when combined with amitriptyline vs headache education plus amitriptyline. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of 135 youth (79 (...) % female) aged 10 to 17 years diagnosed with chronic migraine (≥15 days with headache/month) and a Pediatric Migraine Disability Assessment Score (PedMIDAS) greater than 20 points were assigned to the CBT plus amitriptyline group (n = 64) or the headache education plus amitriptyline group (n = 71). The study was conducted in the Headache Center at Cincinnati Children's Hospital between October 2006 and September 2012; 129 completed 20-week follow-up and 124 completed 12-month follow-up. INTERVENTIONS

JAMA2013

95. Migraine, art and medicine

Migraine, art and medicine Migraine, art and medicine | Evidently Cochrane sharing the latest Cochrane Reviews Search Main menu Post navigation by There’s a man in my mum’s sewing box. Staggeringly handsome and, until recently, rather mysterious. I hadn’t expected to be writing about a mystery again quite so soon after learning of , but today I’m back with new Cochrane evidence which takes some of the mystery out of medicines for migraine, plus a look at migraine art and the man behind (...) it. The man whose face has nestled among the cotton reels for the past sixty years. Migraine is a common, complex and potentially disabling condition. Now we have new evidence from six Cochrane reviews on different drugs used for migraine, two on treating acute migraine and four on preventing episodic migraine in adults. Firstly treament, and two classes of drugs used to treat it, non-steroidal anti-inflammatory drugs (NSAIDs) and triptans. Rick Hutchinson, Migraine Five; We’re in Pain, 1989. (Entry

Evidently Cochrane2013

96. Migraine, art and medicine

Migraine, art and medicine Migraine, art and medicine | Evidently Cochrane sharing the latest Cochrane Reviews Search Main menu Post navigation by There’s a man in my mum’s sewing box. Staggeringly handsome and, until recently, rather mysterious. I hadn’t expected to be writing about a mystery again quite so soon after learning of , but today I’m back with new Cochrane evidence which takes some of the mystery out of medicines for migraine, plus a look at migraine art and the man behind (...) it. The man whose face has nestled among the cotton reels for the past sixty years. Migraine is a common, complex and potentially disabling condition. Now we have new evidence from six Cochrane reviews on different drugs used for migraine, two on treating acute migraine and four on preventing episodic migraine in adults. Firstly treament, and two classes of drugs used to treat it, non-steroidal anti-inflammatory drugs (NSAIDs) and triptans. Rick Hutchinson, Migraine Five; We’re in Pain, 1989. (Entry

Evidently Cochrane2013

97. Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis

Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis Cai X, Song X, Tang H, Huang Y, Xie S, Hu Y CRD summary The authors of this review stated that their results suggested that when steroids were added to standard abortive therapy for migraine headaches they reduced the occurrence (...) of moderate and severe recurrent headaches within 24 to 72 hours and adverse effects were mild. The conclusions of this review appear to be reliable. Authors' objectives To assess the effectiveness and tolerability of steroids for acute migraine headache in adults and the prevention of recurrence of these headaches Searching The authors searched PubMed, EMBASE and The Cochrane Library up to December 2012 with no language or publication restrictions. Search terms were presented. Conference proceedings

DARE.2013

98. Migraine in adults: preventive pharmacologic treatments

Migraine in adults: preventive pharmacologic treatments Migraine in adults: preventive pharmacologic treatments Migraine in adults: preventive pharmacologic treatments Shamliyan TA, Kane RL, Taylor FR Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shamliyan TA, Kane RL, Taylor FR. Migraine in adults: preventive pharmacologic treatments (...) . Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 103. 2013 Authors' objectives To assess comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling adults with episodic or chronic migraine. Authors' conclusions For chronic migraine, onabotulinumtoxin A reduced migraine attacks but increased the risk of adverse effects and treatment discontinuation due to adverse effects. For episodic migraine, approved drugs

Health Technology Assessment (HTA) Database.2013

99. Migraine in children: preventive pharmacologic treatments

Migraine in children: preventive pharmacologic treatments Migraine in children: preventive pharmacologic treatments Migraine in children: preventive pharmacologic treatments Shamliyan TA, Kane RL, Ramakrishnan R, Taylor FR Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shamliyan TA, Kane RL, Ramakrishnan R, Taylor FR. Migraine (...) in children: preventive pharmacologic treatments. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 108. 2013 Authors' objectives To assess the comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling children with episodic or chronic migraine. Authors' conclusions Limited low-strength evidence suggests that propranolol was more effective than placebo for preventing episodic migraine in children, with no bothersome

Health Technology Assessment (HTA) Database.2013

100. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis

Triptans in prevention of menstrual migraine: a systematic review with meta-analysis Triptans in prevention of menstrual migraine: a systematic review with meta-analysis Triptans in prevention of menstrual migraine: a systematic review with meta-analysis Hu Y, Guan X, Fan L, Jin L CRD summary The authors concluded that triptans were an effective short-term prophylactic treatment for menstrual migraines. Considering migraine frequency, severity and adverse events, frovatriptan 2.5mg twice daily (...) and zolmitriptan 2.5mg three times daily were the most preferable regimens. The conclusion regarding the effectiveness of triptans seems reliable; the recommendations for further research were justified. Authors' objectives To evaluate the efficacy and tolerability of triptans in the prevention of menstrual migraine. Searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to October 2012 with no language restrictions. Search terms were reported. Reference lists

DARE.2013